Aclaris Therapeutics, Inc. Common Stock, Value, Issued
Aclaris Therapeutics, Inc. (ACRS) had Common Stock, Value, Issued of $1.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-08-06
- 2026-06-30: Common Stock, Value, Issued $1.00K.
- 2026-03-31: Common Stock, Value, Issued $1.00K.
- 2025-12-31: Common Stock, Value, Issued $1.00K.
- 2025-09-30: Common Stock, Value, Issued $1.00K.
| Period end | Common Stock, Value, Issued |
|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.00K 10-Q · filed 2023-11-06 |
| 2023-06-30 | $1.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.00K 10-Q · filed 2022-08-03 |
| 2022-03-31 | $1.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $1.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |